Innovation Waves in Immuno-oncology Therapy Development

Description

Next-gen Cell Therapies and Precision Immunotherapies are Driving Growth and New Product Development

Immuno-oncology (I-O) therapies target tumors by harnessing the host's immune system. With the growing incidence and prevalence of various types of aggressive and refractory cancers, the next-generation I-O therapy pipeline has witnessed significant growth. Chimeric antigen receptor (CAR)-T cell therapy and tumor-targeted antibody therapies, including monoclonals, antibody-drug conjugates (ADCs), bispecific antibodies, and several therapeutic cancer vaccines, are making rapid strides in clinical trials as effective immunotherapy. This study discusses the key trends and technologies driving the development of such I-O therapies. It delves into advancements in cancer vaccines and cell therapies for various cancer indications, highlighting some of the innovators in this space. Next-generation cell therapies, personalized cancer vaccines, and strategic areas of focus have also been discussed in this report. The study examines the factors driving and restraining this industry and identifies the growth opportunities emerging from the changes in this space for market players and stakeholders to leverage.

Key questions answered in this study:

What does the current clinical landscape of I-O therapies look like?
Which are the technology enablers driving the adoption of I-O therapies?
What are the key developments in adoptive cell therapies and cancer vaccines?
What are the roadblocks to successful translation?
What are the research and development (R&D) focus areas?
What are the key focus areas for the future?

Product Code: DAA2

Strategic Imperatives

Why Is It Increasingly Difficult to Grow? The strategic imperative 8™: Factors creating pressure on growth
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Immuno-Oncology (I-O) Therapeutics Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Research Methodology

Growth Environment: I-O Therapies

Need for Immunotherapy
Scope of Analysis
Segmentation: Snapshot of I-O Therapies
I-O Therapies in Development
Growth Opportunities in I-O Therapy
Growth Drivers
Growth Restraints

Trends and R&D Focus: I-O Therapies

I-O Technology Trends and Developments
Trends in I-O Therapeutics
Therapeutic Development Trends in I-O
R&D Focus Areas to Boost Immunotherapies
Modulation of TME: Solid Tumor Type Determines Therapy
Developing Effective Preclinical Models for Translation
Stakeholders Developing Preclinical Models for I-O Therapy Evaluation
Holistic Tumor Profiling to Boost Precision Oncology Efforts

Emerging I-O Therapeutic Modality Development Landscape

Quick Facts on I-O Therapies
Clinical Development Landscape of I-O Therapies
Cell Therapy to Create the Next Wave of I-O Developments
Cell Therapy Types: Snapshot
Clinical Development Landscape of I-O Cell Therapies
Emerging Areas of Focus to Improve Functionality and Safety Cell Therapies
Next-generation CAR-T Therapy Development
Priority Areas to Improve the Accessibility of Cell Immunotherapy
Innovative Technologies for Cell Therapy Manufacturing and Delivery
Stakeholders Developing Emerging Next-gen Cell Therapies
Potential of Vaccines to Address Challenges with Difficult-to-Treat Cancers
Cancer Vaccine Types
Personalized Neoantigen Vaccines in Clinical Development
Areas of Focus to Bolster Cancer Vaccine Development
RNA Vaccines to Drive the Wave of Prophylactic and Therapeutic Cancer Vaccines
Road Ahead for Cancer Vaccines and Immunotherapy
Emerging Cancer Vaccine
Impact of Emerging Cancer Vaccines Across Cancers

I-O Stakeholder Ecosystem

Regional Trends in I-O Developments and Adoption
Federal Initiatives and Programs Driving I-O Therapy Development
I-O Deals and Investment Trends
Notable Partnerships and Collaborations in I-O, 2023

I-O Regulatory Environment and Reimbursement

I-O: Current Gaps and Potential Opportunities
Strategies to Improve Access and Care Delivery of I-O Therapies

Growth Opportunity Universe

Growth Opportunity 1: Combination Immunotherapies
Growth Opportunity 2: Precision Oncology
Growth Opportunity 3: Advanced Synthetic Biology Platforms
Growth Opportunity 4: Organoids and Organ-on-Chip Models

Appendix

List of a Few Approved ADCs
Approved CAR-T Therapies (global)

Next Steps

Your Next Steps
Why Frost, Why Now?
Legal Disclaimer